Haisco Pharmaceutical Secures US FDA Approval of Cypsedo for Adult General Anesthesia Prior to Surgery 

Shots: 

• The US FDA has approved Cypsedo (Cipepofol) to induce general anesthesia in adults undergoing surgery 

• Cipepofol (Chinese trade name: Sishuning) is China’s first domestically developed Class 1 innovative intravenous anesthetic with global IP rights. It is approved in China for procedural sedation, induction and maintenance of general anesthesia, and ICU sedation during mechanical ventilation 

• In Dec 2020, Cipepofol, approved by China’s NMPA, marked a significant advancement in clinical anesthesia and sedation care. After receiving FDA clearance for clinical trials in 2021, Cipepofol bypassed P-II studies and advanced directly to P-III trials in the US, completing all studies in 2024 with superior results versus the SoC 

Ref: PRnewswire |   Image: Haisco |   Press Release

Related News: Haisco Enters ~$3.05B License and Research Collaboration with Lilly to Develop Novel Medicines Across Multiple Therapeutic Areas

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com